Norovirus, also known as Norwalk virus, is the leading cause of gastroenteritis. It primarily induces symptoms such as non-bloody diarrhea, vomiting, and stomach pain, and may also cause fever and headaches. Symptoms typically appear 12 to 48 hours after exposure and usually resolve within one to three days. While complications are rare, dehydration can occur, particularly in young children, the elderly, and individuals with preexisting health conditions.
In November 1968, an outbreak of acute gastroenteritis at Bronson Elementary School in Norwalk, Ohio, led to the identification of the Norwalk virus, the original name for norovirus. This event marked the beginning of the virus's recognition in the scientific community.
In 1968, an outbreak of norovirus occurred in Norwalk, Ohio, which led to the virus being named after the city. This outbreak marked a significant moment in the history of norovirus.
In 1972, electron microscopy on stored human stool samples identified the Norwalk virus, providing visual confirmation of the virus responsible for outbreaks of acute gastroenteritis.
In December 1998, a person who vomited in a restaurant led to a norovirus outbreak, infecting 52 people. This incident demonstrated the virus's airborne transmission potential and highlighted the importance of controlling such outbreaks.
In 2002, the Farmington Hills virus, a strain of norovirus, was associated with outbreaks in Europe and the United States. This highlighted the global spread and impact of norovirus strains.
In 2002, the International Committee on Taxonomy of Viruses (ICTV) approved the name 'norovirus' for the genus. This formal naming helped standardize the terminology used in scientific and medical communities.
In 2004, the Farmington Hills virus continued to cause norovirus outbreaks in Europe and the United States, showcasing the persistence and widespread nature of the virus.
A 2006 study found that norovirus can survive on surfaces used for food preparation for up to seven days after contamination. This discovery underscored the virus's resilience and the importance of thorough cleaning practices.
In 2006, there was a significant increase in norovirus infections around the globe. Studies linked human histo-blood group antigens (HBGAs) to norovirus susceptibility, suggesting the capsid of noroviruses evolved from selective pressure of human HBGAs.
In 2007, LigoCyte announced the commencement of phase 1 trials for a norovirus vaccine, marking a significant step toward preventing norovirus infections.
In 2011, the CDC released a clinical practice guideline with 51 evidence-based recommendations for preventing and controlling norovirus outbreaks in healthcare settings. This guideline aimed to improve response strategies and reduce infection rates.
In 2011, the ICTV issued a press release encouraging the use of 'Norwalk virus' instead of 'norovirus' to avoid negative associations with the family name 'Noro.' This decision followed consultations with various stakeholders.
In 2012, there was a notable number of norovirus outbreaks on cruise ships, which was later surpassed by an even higher number of outbreaks in 2023.
In 2015, there were 12 norovirus outbreaks on cruise ships, according to the CDC, demonstrating the virus's significant impact on this mode of travel and the need for stringent sanitation measures.
By May 2016, the CDC reported 10 norovirus outbreaks on cruise ships, highlighting the virus's prevalence in such environments. An earlier year, 2015, saw 12 outbreaks, emphasizing the ongoing challenge of controlling norovirus on cruise ships.
In August 2017, more than 700 people were sickened by a norovirus outbreak in Quebec, Canada. The source was identified as frozen raspberries from a Chinese supplier, leading to a recall by Canadian authorities.
In 2019, a bivalent (NoV GI.1/GII.4) intramuscular norovirus vaccine completed phase 1 trials. This vaccine uses a virus-like particle to mimic the external structure of the virus without causing infection.
In 2020, the phase 2b trials for a bivalent norovirus vaccine were completed, bringing the vaccine closer to potential approval and use in preventing norovirus infections.
In 2023, there was a significant increase in norovirus cases on thirteen cruise ships, marking the highest number of outbreaks since 2012, according to the CDC.